Recombinant Human APOC3 protein, MYC/DDK-tagged
Cat.No. : | APOC3-392H |
Product Overview : | Recombinant Human APOC3 fused with MYC/DDK tag at C-terminal was expressed in HEK293. |
- Specification
- Gene Information
- Related Products
- Download
Description : | Apolipoprotein C-III is a very low density lipoprotein (VLDL) protein. APOC3 inhibits lipoprotein lipase and hepatic lipase; it is thought to delay catabolism of triglyceride-rich particles. The APOA1, APOC3 and APOA4 genes are closely linked in both rat and human genomes. The A-I and A-IV genes are transcribed from the same strand, while the A-1 and C-III genes are convergently transcribed. An increase in ap centigrade-III levels induces the development of hypertriglyceridemia. |
Source : | HEK293 |
Species : | Human |
Tag : | MYC/DDK |
Form : | 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol. |
Molecular Mass : | 8.7 kDa |
Purity : | > 80% as determined by SDS-PAGE and Coomassie blue staining |
Concentration : | >50 ug/mL as determined by microplate BCA method |
Gene Name : | APOC3 apolipoprotein C-III [ Homo sapiens ] |
Official Symbol : | APOC3 |
Synonyms : | APOC3; apolipoprotein C-III; apo-CIII; apoC-III; apolipoprotein C3; HALP2; APOCIII; MGC150353; |
Gene ID : | 345 |
mRNA Refseq : | NM_000040 |
Protein Refseq : | NP_000031 |
MIM : | 107720 |
UniProt ID : | P02656 |
Chromosome Location : | 11q23-qter |
Pathway : | Chylomicron-mediated lipid transport, organism-specific biosystem; HDL-mediated lipid transport, organism-specific biosystem; Lipid digestion, mobilization, and transport, organism-specific biosystem; Lipoprotein metabolism, organism-specific biosystem; Metabolism, organism-specific biosystem; Metabolism of lipids and lipoproteins, organism-specific biosystem; PPAR signaling pathway, organism-specific biosystem; |
Function : | cholesterol binding; enzyme regulator activity; high-density lipoprotein particle receptor binding; lipase inhibitor activity; phospholipid binding; |
Products Types
◆ Recombinant Protein | ||
Apoc3-818M | Recombinant Mouse Apoc3 Protein, MYC/DDK-tagged | +Inquiry |
Apoc3-1126M | Recombinant Mouse Apoc3 Protein, His-SUMO-tagged | +Inquiry |
APOC3-635M | Recombinant Mouse APOC3 Protein, His (Fc)-Avi-tagged | +Inquiry |
APOC3-1333R | Recombinant Rat APOC3 Protein (21-101 aa), His-tagged | +Inquiry |
APOC3-2235C | Recombinant Cynomolgus Monkey APOC3 Protein (21-99 aa), His-SUMOSTAR-tagged | +Inquiry |
◆ Native Protein | ||
APOC3-27333TH | Native Human APOC3 | +Inquiry |
APOC3-8040H | Native Human ApoLipoprotein CIII | +Inquiry |
APOC3-669H | Native Human APOC3 protein | +Inquiry |
◆ Lysates | ||
APOC3-8782HCL | Recombinant Human APOC3 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (17)
Ask a questionYes, there are several methods that have been shown to lower APOC3 levels in the body. Lifestyle changes such as regular exercise, a healthy diet, and weight loss can reduce APOC3 levels. Certain medications, such as fibrates and omega-3 fatty acids, have also been found to effectively decrease APOC3 levels. Additionally, emerging therapeutic approaches targeting APOC3, as mentioned earlier, are being developed to directly inhibit its production or activity.
Yes, lifestyle modifications can help manage elevated APOC3 protein levels. A healthy diet low in saturated fats and refined carbohydrates, regular physical activity, and weight management can help control triglyceride levels and promote cardiovascular health.
While there may not be specific support groups solely dedicated to APOC3-related conditions, several organizations and resources focus on lipid disorders and cardiovascular health. The National Lipid Association and the American Heart Association are among the organizations that provide information, resources, and support for individuals and families impacted by lipid metabolism disorders.
Yes, there are targeted therapies being developed to reduce APOC3 levels. One approach is the use of antisense oligonucleotides (ASOs), which are synthetic molecules designed to specifically target the APOC3 mRNA and inhibit its production. ASOs have shown promise in clinical trials, with some studies demonstrating significant reductions in APOC3 levels and improvements in lipid profiles. Another approach being explored is the use of gene editing technologies, such as CRISPR-Cas9, to directly modify the APOC3 gene and reduce its expression.
The APOC3 protein is primarily synthesized in the liver, but it can also be produced in the intestines. The APOC3 gene is transcribed into messenger RNA (mRNA), which is then translated in the cytoplasm of cells to ultimately produce the APOC3 protein.
Yes, variations in the APOC3 gene have been identified. Some mutations can lead to an increase in APOC3 protein levels, resulting in high triglyceride levels, which is a risk factor for cardiovascular disease.
Some natural substances have shown potential in reducing APOC3 levels. For example, certain dietary components like polyphenols found in fruits, vegetables, and tea have been found to decrease APOC3 expression and inhibit its production. However, more research is needed to fully understand the effects and mechanisms of these natural substances on APOC3 levels.
Yes, mutations in the APOC3 gene have been associated with other health conditions besides FCS. Studies have identified APOC3 gene variants that are linked to increased risk of cardiovascular disease, metabolic disorders such as insulin resistance and type 2 diabetes, and non-alcoholic fatty liver disease.
While reducing APOC3 levels has shown promise in improving lipid profiles and reducing cardiovascular risk, there are potential side effects and risks to consider. Modulating APOC3 levels can affect lipid metabolism and may lead to changes in other lipoprotein components, including HDL (high-density lipoprotein) and LDL (low-density lipoprotein) cholesterol. This could potentially impact overall lipid balance and cardiovascular health.
Yes, genetic testing can identify mutations in the APOC3 gene that may result in elevated APOC3 levels and increased triglyceride levels. Testing for these genetic variations can help identify individuals who are at a higher risk of developing conditions related to elevated APOC3 protein levels.
There are ongoing research efforts to develop medications that target the APOC3 protein. One example is the drug known as volanesorsen, which is being investigated for its potential to lower triglyceride levels in individuals with specific genetic mutations.
APOC3 levels can be measured or tested in clinical settings using various laboratory techniques. One common method is through the measurement of APOC3 concentration in blood samples using immunoassays, such as enzyme-linked immunosorbent assay (ELISA) or nephelometry. These techniques use specific antibodies that bind to APOC3 and allow for its quantification. Other methods, such as genetic testing or sequencing, can be used to identify mutations or genetic variants in the APOC3 gene that may affect APOC3 levels.
Elevated levels of APOC3 protein are associated with an increased risk of cardiovascular disease, as it can lead to high triglyceride levels and impaired lipid metabolism. This can contribute to the development of conditions like hypertriglyceridemia and may increase the risk of atherosclerosis.
APOC3 levels have been studied as potential biomarkers for various diseases. Elevated APOC3 levels have been associated with increased risk of cardiovascular disease, metabolic disorders, and non-alcoholic fatty liver disease. However, further research is needed to establish APOC3 levels as definitive biomarkers and to determine their clinical utility in diagnosing and monitoring these diseases.
Yes, there is a connection between APOC3 and obesity. Obesity is often associated with elevated levels of triglycerides and APOC3, which can contribute to the development of metabolic disorders, insulin resistance, and cardiovascular disease. Therefore, reducing APOC3 levels may be beneficial in managing obesity-related health conditions.
Yes, various therapeutic approaches are being explored to target APOC3 and lower triglyceride levels. These include the development of monoclonal antibodies, antisense oligonucleotides, and small interfering RNA (siRNA) therapies that specifically inhibit the production or activity of APOC3 protein.
Apart from its role in lipid metabolism, the APOC3 protein has been implicated in other physiological processes. Studies suggest that it may have anti-inflammatory properties, play a role in regulating insulin sensitivity and glucose metabolism, and be involved in modulating the immune response.
Customer Reviews (4)
Write a reviewthe manufacturer's supply management capabilities assure a seamless and continuous provision of the APOC3 protein.
I am confident that the protein will reliably perform in my assays, providing accurate and reproducible results.
the manufacturer's supply management capabilities assure a seamless and continuous provision of the APOC3 protein.
Their ability to accommodate the requirements of large-scale experiments and guarantee a reliable supply streamlines my research operations, eliminating any concerns related to potential shortages.
Ask a Question for All APOC3 Products
Required fields are marked with *
My Review for All APOC3 Products
Required fields are marked with *
Inquiry Basket